To further determine whether DTLL was capable of sensitizing cells to other drugs, we selected multiple antineoplastic agents widely used for pancreatic cancer treatment to detect the effect of DTLL combined with 5-fluorouracil (antimetabolite), oxaliplatin (DNA cross-linking), paclitaxel (anti-microtubule), irinotecan (topoisomerase I inhibitor), etoposide (topoisomerase II inhibitor) and lapatinib (dual HER2 and EGFR tyrosine kinase inhibitor), followed by evaluation of the synergistic effect by combination index (CI) calculation. The gene discussed is ERBB2; the disease is pancreatic neoplasm.